Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile

The dose-dependent and time-dependent effects of the novel antipsychotic compound remoxipride, as well as the reference compounds chlorpromazine, clozapine, haloperidol, pimozide and sulpiride upon the retention of two-way active avoidance (conditioned avoidance responses, CARs) were studied in male rats. The dose-dependent effects of remoxipride as well as haloperidol and chlorpromazine on the acquisition of CARs were also studied. The acquisition and retention of CARs were tested in shuttleboxes using a 1.0-mA shock intensity and a 10-stone signal (1000 Hz). All the compounds studied, including remoxipride, caused a dose-dependent impairment of acquisition and retention of CARs. The effect of remoxipride on CAR acquisition correlated with remoxipride's effectiveness to block the hyperactivity induced by the dopamine (DA) agonist apomorphine. Unlike chlorpromazine and haloperidol, the potency of remoxipride and clozapine for antagonising CAR retention was found at dose levels much lower than those producing cataleptic effects or blocking apomorphine-induced stereotypies. Based on the DA receptor blocking profile and the relative effectiveness to block CAR it is concluded that the mechanism(s) by which clozapine and remoxipride affect CAR differ from typical neuroleptic drugs. This difference may reflect an action upon different subtypes of functionally coupled DA D2 receptors.

[1]  D. Coward,et al.  Biochemical and behavioural properties of clozapine , 2004, Psychopharmacology.

[2]  A. Barnett,et al.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. , 1983, The Journal of pharmacology and experimental therapeutics.

[3]  C. Köhler,et al.  Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain , 2005, Journal of Neural Transmission / General Section JNT.

[4]  Donald Posluns,et al.  An analysis of chlorpromazine-induced suppression of the avoidance response , 1962, Psychopharmacologia.

[5]  I. Weiner.  Neural substrates of latent inhibition: the switching model. , 1990, Psychological bulletin.

[6]  J. Krystal,et al.  Psychopharmacology: The Third Generation of Progress , 1989, The Yale Journal of Biology and Medicine.

[7]  R. Beninger.  The role of dopamine in locomotor activity and learning , 1983, Brain Research Reviews.

[8]  P. Sen.  Estimates of the Regression Coefficient Based on Kendall's Tau , 1968 .

[9]  J. Arnt,et al.  Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. , 2009, Acta pharmacologica et toxicologica.

[10]  A. Phillips,et al.  Haloperidol-induced disruption of conditioned avoidance responding: attenuation by prior training or by anticholinergic drugs. , 1975, European journal of pharmacology.

[11]  S. Ahlénius,et al.  Suppression of conditioned avoidance behavior by the local application of (−)sulpiride into the ventral, but not the dorsal, striatum of the rat , 1990, Biological Psychiatry.

[12]  J. Hyttel.  Further evidence that 3H-cis(Z)flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum , 2004, Psychopharmacology.

[13]  H. Hall,et al.  The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions , 2004, Psychopharmacology.

[14]  Anthony G. Phillips,et al.  Blockade of acquisition of one-way conditioned avoidance responding by haloperidol and metoclopramide but not by thioridazine or clozapine: implications for screening new antipsychotic drugs , 2004, Psychopharmacology.

[15]  R. Hamburger,et al.  Natriuretic and phosphaturic response to diuretics after parathyroidectomy in dogs. , 1977, European journal of pharmacology.

[16]  C J Niemegeers,et al.  A systematic study of the pharmacological activities of dopamine antagonists. , 1979, Life sciences.

[17]  G. Koob,et al.  Neuroleptic-like distruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems , 1984, Brain Research.

[18]  T. Archer.  Signalled and unsignalled avoidance impairments following noradrenaline depletion with DSP4: an hypothesis incorporating an associative and a non-associative factor. , 1983, Scandinavian journal of psychology.

[19]  C J Niemegeers,et al.  Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? , 1966, Arzneimittel-Forschung.

[20]  R. George,et al.  Subcellular localization of dopamine-sensitive adenylate cyclase and dopamine receptor binding activities. , 1978, Life sciences.

[21]  V. Coffin,et al.  Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats. , 1991, The Journal of pharmacology and experimental therapeutics.

[22]  H. Hall,et al.  Neuropharmacological and behavioural properties of remoxipride in the rat , 1990, Acta psychiatrica Scandinavica. Supplementum.

[23]  S. T. Mason,et al.  The use of conditioned suppression to evaluate the nature of neuroleptic-induced avoidance deficits. , 1980, The Journal of pharmacology and experimental therapeutics.

[24]  O. Hornykiewicz,et al.  The role of the corpus striatum in neuroleptic- and narcotic-induced catalepsy. , 1978, European journal of pharmacology.

[25]  T. Archer,et al.  DSP4-induced two-way active avoidance impairment in rats: Involvement of central and not peripheral noradrenaline depletion , 2004, Psychopharmacology.

[26]  K. Fuxe,et al.  Learning, brain noradrenaline and the pituitary--adrenal axis. , 1974, Medical biology.

[27]  R. Wise,et al.  Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food. , 1978, Science.

[28]  P. H. Andersen.  Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. , 1988, European journal of pharmacology.

[29]  D. Jackson,et al.  Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.

[30]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[31]  C. A. Stone,et al.  Antagonism of the antiavoidance effects of various agents by anticholinergic drugs. , 1970, The Journal of pharmacology and experimental therapeutics.

[32]  A. Graybiel.  Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.

[33]  J. Hyttel.  A comparison of the effect of neuroleptic drugs on the binding of 3H-haloperidol and 3H-cis(Z)-flupenthixol and on adenylate cyclase activity in rat striatal tissue in vitro , 1978 .

[34]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[35]  B. Costall,et al.  Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate‐putamen , 1977, The Journal of pharmacy and pharmacology.

[36]  A. Catania,et al.  EFFECTS OF DRUGS ON AVOIDANCE AND ESCAPE BEHAVIOR. , 1964, Federation proceedings.

[37]  A. Cools,et al.  The involvement of the nucleus accumbens in the ability of rats to switch to cue-directed behaviours. , 1989, Life sciences.

[38]  H. Pakkenberg,et al.  Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped, aggressive and cataleptic behaviour , 2004, Psychopharmacologia.

[39]  A. Cools,et al.  Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: Tonic EMG activity in rats , 1985, Brain Research.

[40]  M. Eigyo,et al.  Differential effects of sulpiride and metoclopramide on brain , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[41]  S COURVOISIER,et al.  Pharmacodynamic basis for the use of chlorpromazine in psychiatry. , 1956, Journal of clinical and experimental psychopathology.

[42]  P. Voorn,et al.  Development of Dopamine - Containing Systems in the CNS , 1992 .

[43]  A. Barnett,et al.  Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. , 1984, Life sciences.

[44]  A. Phillips,et al.  Reversal by L-Dopa of Impaired Learning Due to Destruction of the Dopaminergic Nigro-Neostriatal Projection , 1974, Science.

[45]  P. Spano,et al.  Sulpiride: a study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. , 1975, Life sciences.

[46]  Biochemical pharmacology of the atypical neuroleptic remoxipride , 1990 .

[47]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[48]  H. Hall,et al.  Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. , 1984, European journal of pharmacology.

[49]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[50]  A. Phillips,et al.  Deficits in Instrumental Responding after 6-Hydroxydopamine Lesions of the Nigro-Neostriatal Projection , 1974 .

[51]  W. Schultz,et al.  Responses of monkey midbrain dopamine neurons during delayed alternation performance , 1991, Brain Research.

[52]  H. Hall,et al.  Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. , 2009, Acta Pharmacologica et Toxicologica.